Research Analysts’ Weekly Ratings Changes for Genmab A/S (GMAB)

A number of firms have modified their ratings and price targets on shares of Genmab A/S (NASDAQ: GMAB) recently:

• 10/30/2026 – Genmab A/S had its price target raised by Morgan Stanley from $42.00 to $57.00. They now have an “equal weight” rating on the stock.
• 10/30/2026 – Genmab A/S had its price target raised by Guggenheim from $58.00 to $80.00. They now have a “buy” rating on the stock.
• 10/29/2026 – Genmab A/S had its “buy” rating reaffirmed by Truist Financial. They now have a $67.00 price target on the stock, up from $45.00.
• 10/29/2026 – Genmab A/S had its price target raised by HC Wainwright from $50.00 to $70.00. They now have a “buy” rating on the stock.
• 10/26/2026 – Genmab A/S had its price target raised by TD Cowen from $43.00 to $52.00. They now have a “buy” rating on the stock.
• 10/26/2026 – Genmab A/S was upgraded by JPMorgan Chase & Co. from “neutral” to “overweight”.
• 10/20/2026 – Genmab A/S was given a new $42.00 price target by Morgan Stanley.
• 10/7/2026 – Genmab A/S had its price target raised by Truist Financial from $40.00 to $45.00. They now have a “buy” rating on the stock.
• 10/7/2026 – Genmab A/S had its price target raised by HC Wainwright from $40.00 to $50.00. They now have a “buy” rating on the stock.
• 10/5/2026 – Genmab A/S had its price target raised by Guggenheim from $45.00 to $54.00. They now have a “buy” rating on the stock.
• 9/14/2026 – Genmab A/S had its “buy” rating reaffirmed by HC Wainwright. They now have a $40.00 price target on the stock.

Genmab A/S Trading Up 1.1%

Shares of NASDAQ:GMAB traded up $0.60 during mid-day trading on Tuesday, reaching $55.52. The stock had a trading volume of 3,039,846 shares, compared to its average volume of 2,491,838. The firm has a 50 day simple moving average of $37.55 and a two-hundred day simple moving average of $30.69. Genmab A/S Sponsored ADR has a twelve month low of $23.62 and a twelve month high of $59.97. The firm has a market cap of $34.65 billion, a PE ratio of 43.72, a price-to-earnings-growth ratio of 2.47 and a beta of 0.81. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Thursday, August 6th. The company reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a return on equity of 14.89%. On average, research analysts predict that Genmab A/S Sponsored ADR will post 1.22 EPS for the current fiscal year.

Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on discovering and developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including DuoBody and HexaBody, to create therapies designed to engage the immune system or target specific disease-related proteins.

Genmab’s marketed and partnered products include DARZALEX (daratumumab) for multiple myeloma, developed with Johnson & Johnson; EPKINLY (epcoritamab) for certain types of B-cell lymphoma, developed with AbbVie; and Tivdak (tisotumab vedotin) for cervical cancer, developed with Seagen.